4D Molecular Therapeutics, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp has disclosed a stake exceeding 5% in 4D Molecular Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000602). The passive-investor disclosure signals meaningful institutional ownership in the clinical-stage gene therapy developer. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G/13D amendments and quarterly 13F updates for changes in State Street's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, 4D Molecular Therapeutics, Inc.